ReviewDrug design, development and therapy2014
Ivabradine, coronary artery disease, and heart failure: beyond rhythm control.
Review in Drug design, development and therapy, 2014. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 17 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
17 citing papers in PubMed.
- Ivabradine as a Cardio-Protective Agent Against Anthracycline-Induced Cardiotoxicity: A Narrative Review.Cardiovascular drugs and therapy · 2026Review
- Chronic administration of ivabradine improves cardiac Ca handling and function in a rat model of Duchenne muscular dystrophy.Scientific reports · 2025Article
- Effect of 24-hour heart rate fluctuations on mortality in patients with acute myocardial infarction: based on the MIMIC III database.BMC cardiovascular disorders · 2025Article
- Ranolazine: An Established Anti-anginal Drug with Emerging Antidiabetic Potential Supported by Preclinical and Clinical Evidence.Cardiovascular & hematological disorders drug targets · 2025Review
- New Therapeutics for Heart Failure: Focusing on cGMP Signaling.International journal of molecular sciences · 2023Review
- The effect of ivabradine therapy on dilated cardiomyopathy patients with congestive heart failure: a systematic review and meta-analysis.Frontiers in cardiovascular medicine · 2023Review
- Frequency-Dependent Properties of the Hyperpolarization-Activated Cation Current, IInternational journal of molecular sciences · 2022Article
- The Bradycardic Agent Ivabradine Acts as an Atypical Inhibitor of Voltage-Gated Sodium Channels.Frontiers in pharmacology · 2022Article
- The promise and problems of metabolic-based therapies for heart failure.Interventional cardiology · 2021Article
- Ivabradine Monotherapy for the Treatment of Congenital Junctional Ectopic Tachycardia in a Premature Neonate.The journal of pediatric pharmacology and therapeutics : JPPT : the official journal of PPAG · 2021Article
- Association of pulse rate with outcomes in heart failure with reduced ejection fraction: a retrospective cohort study.BMC cardiovascular disorders · 2020Observational
- Sequence analysis and variant identification at the APOC3 gene locus indicates association of rs5218 with BMI in a sample of Kuwaiti's.Lipids in health and disease · 2019Article
- A New Mechanism of Action in Heart Failure: Angiotensin-Receptor Neprilysin Inhibition.The Journal of pharmacy technology : jPT : official publication of the Association of Pharmacy Technicians · 2016Review
- Review
- Age-associated expression of HCN channel isoforms in rat sinoatrial node.Experimental biology and medicine (Maywood, N.J.) · 2016Article
- Elevated Total Homocysteine Levels in Acute Ischemic Stroke Are Associated With Long-Term Mortality.Stroke · 2015Article
- hERG potassium channel blockade by the HCN channel inhibitor bradycardic agent ivabradine.Journal of the American Heart Association · 2015Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
14 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Elevated heart rate could negatively influence cardiovascular risk in the general population. It can induce and promote the atherosclerotic process by means of several mechanisms involving endothelial shear stress and biochemical activities. Furthermore, elevated heart rate can directly increase heart ischemic conditions because of its skill in unbalancing demand/supply of oxygen and decreasing the diastolic period. Thus, many pharmacological treatments have been proposed in order to reduce heart rate and ameliorate the cardiovascular risk profile of individuals, especially those suffering from coronary artery diseases (CAD) and chronic heart failure (CHF). Ivabradine is the first pure heart rate reductive drug approved and currently used in humans, created in order to selectively reduce sinus node function and to overcome the many side effects of similar pharmacological tools (ie, β-blockers or calcium channel antagonists). The aim of our review is to evaluate the role and the safety of this molecule on CAD and CHF therapeutic strategies.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.